V

Vanda Pharmaceuticals
D

VNDA

5.63000
USD
-0.205
(-3.51%)
Market Closed
Volume
25,636
EPS
0
Div Yield
0
P/E
-25
Market Cap
282,122,671
Related Instruments
    ABBV
    4.380
    (2.36%)
    189.700 USD
    AMGN
    2.78
    (0.84%)
    335.22 USD
    B
    BIIB
    -2.500
    (-1.17%)
    210.710 USD
    B
    BMRN
    0.270
    (0.32%)
    84.620 USD
    GILD
    0.470
    (0.62%)
    76.510 USD
    I
    INCY
    -0.680
    (-1.05%)
    64.390 USD
    LLY
    28.47
    (3.54%)
    832.74 USD
    MRK
    0.680
    (0.60%)
    113.800 USD
    REGN
    13.14
    (1.22%)
    1,091.19 USD
News

Title: Vanda Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products, HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS), Fanapt for the treatment of schizophrenia and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from HETLIOZ product sales.